Mannose ameliorates experimental colitis by protecting intestinal barrier integrity

Metabolite alteration has been associated with the pathogenesis of inflammatory bowel disease (IBD), including colitis. Mannose, a natural bioactive monosaccharide that is involved in metabolism and synthesis of glycoproteins, exhibits anti-inflammatory and anti-oxidative activities. We show here that the circulating level of mannose is increased in patients with IBD and mice with experimental colitis. Mannose treatment attenuates intestinal barrier damage in two mouse colitis models, dextran sodium sulfate (DSS)-induced colitis and spontaneous colitis in IL-10-deficient mice. We demonstrate that mannose treatment enhanced lysosomal integrity and limited the release of cathepsin B, preventing mitochondrial dysfunction and myosin light chain kinase (MLCK)-induced tight junction disruption in the context of intestinal epithelial damage. Mannose exerts a synergistic therapeutic effect with mesalamine on mouse colitis. Cumulatively, the results indicate that mannose supplementation may be an optional approach to the treatment of colitis and other diseases associated with intestinal barrier dysfunction.


Statistics
For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.
n/a Confirmed The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly The statistical test(s) used AND whether they are one-or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.
A description of all covariates tested A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals) For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted Give P values as exact values whenever suitable.

For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes Estimates of effect sizes (e.g. Cohen's d, Pearson's r), indicating how they were calculated Our web collection on statistics for biologists contains articles on many of the points above.

Software and code
Policy information about availability of computer code Data collection

Data analysis
For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.

Data
Policy information about availability of data All manuscripts must include a data availability statement. This statement should provide the following information, where applicable: Field-specific reporting Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

Life sciences Behavioural & social sciences Ecological, evolutionary & environmental sciences
For a reference copy of the document with all sections, see nature.com/documents/nr-reporting-summary-flat.pdf

Life sciences study design
All studies must disclose on these points even when the disclosure is negative. In Vivo experiments were performed using a sample size of n=6-10 mice per arm unless noted otherwise. Power analysis was used to decide on the number of mice per group. For immunofluorescence analysis, multiple fields of view per slide were quantified, and exact numbers are specified in the methods section of the paper. In most experiments, at least three biological repeats were performed. The number of patients included in the study was determined by the availability of patients' specimens.
No data was excluded for this study.
Unless specified, data were representative of three independent experiments. All the experiments and analyses shown could be successfully and reliably replicated and reproduced.
Before the experiments, all the samples were grouped randomly for each participant, and repeat these results at different time.
All the experiments were double blinded. One of the participant prepare samples, another one perform the experiments, finally all participants analyzed the results together.  The main test for authenticating NCM460 cells is short tandem repeat (STR) profiling, the analysis of microsatellite regions of DNA that have variable numbers of repeats and are located throughout the genome. PCR amplicons are generated using primers for regions that flank these polymorphic sites. After amplification, PCR products are resolved using capillary electrophoresis, and a profile for these repetitive regions is created.
I confirmed that NCM460 cells tested negative for mycoplasma contamination.
There were no misidentified cells in our studies.
This study did not involve wild animals.
This study did not involve samples collected from the field.
All animal procedures were approved by the welfare and Ethical Committee for Experimental Animal Care of Southern Medical University.
Demographics of all patients in the study were provided in Supplementary Table 1. Serum were collected from patients the first time they are diagnosed or from healthy volunteers during physical examination.
The study was reviewed and approved by Medical Ethics Committee of Nanfang hospital.